NCT02227368

Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR

A Phase II Multicentre, Randomised, Double-Blind, Controlled, Parallel-Group Study to Evaluate the Walking Time Effect of Long-Term Ticagrelor in Comparison to Long-Term Aspirin Administration in Ambulatory Patients With Peripheral Artery Disease Undergoing Endovascular Revascularization - The Ticagrelor in Peripheral Artery Disease Endovascular Revascularization Study TI-PAD I EVR

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 50 Years – 130 Years
• Healthy volunteers: Not accepted

Summary

To compare the effect of ticagrelor versus aspirin on the change in peak walking time, evaluated on the graded treadmill test, from one to 26 weeks post-revascularization in patients with peripheral artery disease who have undergone endovascular revascularization for moderate to severe claudication or ischemic rest pain.

Detailed description

A Phase II Multicentre, Randomised, Double-Blind, Controlled, Parallel-Group Study to Evaluate the Walking Time Effect of Long-Term Ticagrelor in Comparison to Long-Term Aspirin Administration in Ambulatory Patients with Peripheral Artery Disease Undergoing Endovascular Revascularization - The Ticagrelor in Peripheral Artery Disease Endovascular Revascularization Study TI-PAD I EVR.

Conditions

• Peripheral Artery Disease (PAD)

Interventions

Type	Name	Description
DRUG	Ticagrelor	Antiplatelet therapy approved for ACS. Antagonist of P2Y12 and inhibitor of adenosine diphosphate (ADP)-induced platelet aggregation.
DRUG	Comparator	Aspirin monotherapy anti-platelet treatment for PAD patients following EVR procedures

Timeline

• Start date: 2014-10-20
• Primary completion: 2016-05-23
• Completion: 2016-05-23
• First posted: 2014-08-28
• Last updated: 2017-07-19
• Results posted: 2017-06-14

Locations

10 sites across 1 country: United States